

For more information go to www.barrx.com

**SCHEDULE OF ACCEPTED DDW CLINICAL ABSTRACTS INCLUDING
THE HALO ABLATION TECHNOLOGY
FOR THE TREATMENT OF BARRETT'S ESOPHAGUS**

DDW and Medical Societies' Sponsored Podium Presentations at the San Diego Convention Center

SSAT Presidential: Plenary A (Plenary Session I). Monday, May 19, 8:15 a.m., Room #25

Abstract ID # 215: Stepwise circumferential and focal radiofrequency ablation of Barrett's esophagus with high-grade dysplasia or intramucosal cancer (J. J. Bergman, et al)

AGA Institute: Clinical Science Plenary, Monday, May 19, 8:35 a.m., Room# 20BCD

Abstract ID # 213: A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (BE) Containing Dysplasia: Interim Results of the AIM Dysplasia Trial (N. J. Shaheen, et al)

ASGE: Clinical Endoscopic Ultrasound, Tuesday, May 20, 2:27 p.m., Room #1

Abstract ID# 761: The Utility of Endoscopic Ultrasound (EUS) In Patients With Barrett's Esophagus (BE) and High Grade Dysplasia (HGD): Analysis of the AIM Dysplasia Trial Experience (R. Muthusamy, et al)

DDW and Medical Societies' Sponsored Poster Sessions at the San Diego Convention Center

Sails Pavilion – Posters will be on display from 8:00 a.m. to 5:00 p.m. with an author present at the poster location between 12:00 p.m. and 2:00 p.m.

ASGE: Endoscopic Technology, Sunday, May 18th

ID # S1441: Stepwise circumferential and focal radiofrequency energy ablation of Barrett's esophagus with early neoplasia: first European multi-centre trial (R.E. Pouw, et al)

ID # S1475: Complications following circumferential radiofrequency energy ablation of Barrett's esophagus containing early neoplasia (R. E. Pouw, et al.)

ASGE: Esophagus, Monday, May 19th

ID # M1295: Clinical and endoscopic characteristics of a large cohort of Barrett's esophagus (BE) patients with low and high-grade dysplasia (P. Sharma, et al)

ID # M1305: Subsquamous intestinal metaplasia is a common finding in ablation-naïve patients with dysplastic Barrett's esophagus, and significantly decreases in prevalence after radiofrequency ablation (N. J. Shaheen, et al)

ID # M1321: Interim Analysis of Barrett's esophagus eradication by radiofrequency ablation (J.C. Hernandez, et al)

ID # M1323: A promising new combined treatment modality for Barrett's esophagus containing early neoplasia: endoscopic resection followed by step-wise circumferential and focal radiofrequency energy ablation (R. E. Pouw, et al)

ID #M1326: Predictors and quantitative assessment of incomplete response after radiofrequency ablation for dysplastic Barrett's esophagus: Analysis of randomized sham-controlled clinical trial (The AIM Dysplasia Trial) (C. J. Lightdale, et al)

For more information go to www.barrx.com

AGA Institute: Barrett's Esophagus Diagnosis and Management, Monday, May 19th

- ID # M1933:** Biopsy yield of dysplastic Barrett's esophagus based on location within the Barrett's segment (E. S. Dellon, et al)
- ID # M1935:** Stepwise circumferential and focal radiofrequency ablation of Barrett's esophagus preserves esophageal diameter, compliance and motility (H. Beaumont, et al)
- ID # M1942:** Comparison of Catheter-Based Radiofrequency Ablation and Photodynamic Therapy for Barrett's Esophagus (J. M. Bumgarner, et al)

AGA Institute: Barrett's Esophagus Diagnosis and Management, Monday, May 19th

- ID # M1944:** The molecular pathology of radiofrequency mucosal ablation of Barrett's esophagus (D. Finkelstein, et al)

AGA Institute GERD, Barrett's Esophagus, and Esophageal Cancer: Monday, May 19

- ID #M1030:** Impact of Barrett's esophagus containing dysplasia on patient quality of life: Interim results of a randomized, sham-controlled trial of radiofrequency ablation (AIM Dysplasia Trial) (N. J. Shaheen, et al)

SSAT: Session I Clinical/Colon Rectal , Monday, May 19th

- ID #M1510:** Dosimetric Evaluation of Endoscopic Radiofrequency Ablation in the Human Colonic Epithelium in a Treat and Resect Trial (J. A. Trunzo, et al)

AGA Institute: Endoscopic Detection of Premalignant Lesions of the UGI Tract, Wednesday, May 21st

- ID #W1876:** Are biopsies after ablation for dysplastic Barrett's esophagus of adequate depth to detect glandular mucosa beneath the neosquamous epithelium? – Comparative histopathological outcomes from a randomized, sham-controlled trial (AIM Dysplasia Trial) (N. J. Shaheen, et al)